Home / Transcripts / CRA International, Inc. (CRAI) · October 30, 2025

CRA International, Inc. (CRAI) Earnings Call Transcript

October 30, 2025

NASDAQ US Industrials Professional Services earnings 40 min

Earnings Call Speaker Segments

Eric Nierenberg executive
#1

Thanks, Rob, and hello everybody. I want to point out that anything we say on this call — such as our outlook for upcoming revenue and non-GAAP EBITDA margin, plus any other remarks about CRA's future operating results or financial condition, including those that use the words expect, outlook, or similar wording — counts as forward-looking statements under Section 21 of the Exchange Act. The content of these forward-looking statements rests on what management currently anticipates and is by nature uncertain. A variety of significant factors — among them the degree of demand for what we offer, driven by shifts in broader and industry-specific economic conditions — could cause actual performance and results to vary materially from what those statements express or imply. Further details about these factors appear in today's release and in CRA's periodic reports, such as our latest Annual Report on Form 10-K and the quarterly reports on Form 10-Q we file with the SEC. CRA is not obligated to refresh any forward-looking statements after today's call date. Also, we'll be citing a few non-GAAP financial measures and some figures given on a constant currency basis during this call. We urge everyone to look at today's release and the accompanying CFO remarks for reconciliations of those non-GAAP financial measures to their GAAP counterparts, along with explanations of how EBITDA and constant currency figures are calculated. At this point I'll hand things over to Paul for his report. Paul

Paul Maleh executive
#2

Eric, thank you, and good morning, everyone. We're glad you could join us. As we moved into the third quarter of fiscal 2025, CRA continued its run of strong results. Revenue increased 10.8% compared with the same period a year earlier, coming in at $185.9 million. Combined with the record top-line figures posted in the first and second quarters, that means fiscal 2025 has produced the three best revenue quarters in CRA's history, which shows just how resilient CRA's business model is. The third quarter's performance was broad-based, with year-over-year growth in seven of eleven practices. Our antitrust and competition economics group, along with energy, finance, and intellectual property, all delivered revenue increases in the double digits. We also saw growth geographically — North American revenue was up 6.8%, and our operations outside the US rose 30.3% compared with the same period last year. The strongest contributors to that impressive international performance were our antitrust and competition economics and life sciences practices. Despite this stretch of strong growth, we've continued to run the business well, and utilization for the quarter reached 77%. Thanks to solid utilization and strong execution overall, profitability improved faster than revenue did year over year — non-GAAP net income climbed 12.7%, earnings per diluted share increased 16.4%, and EBITDA was up 14.6%. For the third quarter, revenue from CRA's legal and regulatory services rose 11.5%. That gain was underpinned by activity in the broader legal market, since total case filings and total court judgments each rose by double-digit percentages relative to activity in the third quarter of 2024. Building on ongoing merger-related activity and sustained demand for antitrust services, our antitrust and competition economics practice set yet another quarterly revenue record. The practice keeps supporting clients on high-profile mergers, as worldwide M&A activity came to $3 trillion during the first nine months of 2025, up 33% from year-ago levels and the strongest opening period for deal making since 2021. In the third quarter, for instance, CRA's competition practice advised UnitedHealth Group in connection with the U.S. The Justice Department examined UnitedHealth's planned $3.3 billion purchase of Amedisys. At first the DOJ tried to stop the deal, but it later said it had worked out a settlement with UnitedHealth Group and Amedisys, which let the transaction move forward. After regulators spent two years looking at the matter, CRA's competition team lent its know-how across the DOJ's investigation and the related litigation. That practice group also helped drive the solid gains posted by CRA's overseas business; in one instance, a CRA team spent the third quarter giving Microsoft economic analysis and support while authorities probed its Teams collaboration platform. Come September 2025, the European Commission said it had closed that lengthy investigation by accepting commitments from Microsoft aimed at easing EU competition worries. In other areas, our finance group stayed busy handling matters spanning multiple sectors and courtrooms. For instance, CRA has been working with a client in the chemicals and agricultural products sector on litigation with a lot at stake, centered on claims of contract violations and anticompetitive behavior. Over the most recent quarter, CRA assisted in advancing and resolving conflicts tied to structured data production, the development and assessment of possible damages, and preparation for mediation. In another matter, CRA was engaged to provide expert testimony on financial questions in the NASCAR antitrust case, which is scheduled to go to trial in December. Across Q3, CRA's IP division offered advice on many major litigation and valuation matters. In a patent infringement matter involving mRNA COVID-19 vaccines, one of CRA's experts gave testimony regarding reasonable royalty damages that took into account various liability scenarios and recovery periods. The party then reached a global settlement that resolved all pending U.S. litigation tied to COVID-19 vaccines and created a framework for resolving ongoing patent disputes outside the U.S. once the defendant acquired CRA's client for roughly $1.25 billion. As part of the settlement terms, CRA's client and its partners are also set to receive a $740 million payment plus royalties on U.S. sales of COVID-19 vaccines. Looking ahead, we also experienced robust activity in our transfer pricing services during Q3. Tax authorities around the world keep transfer pricing near the top of their agendas, so CRA's specialists stay busy helping clients resolve disagreements. Everywhere, clients want economic analysis that pulls together people from different practices; take our Competition and Transfer Pricing teams, which are working with a large mining company to confirm that what it charges related parties can't be characterized as predatory pricing under antitrust rules. Management consulting revenue rose 8% compared with a year earlier, lifted by excellent results in our energy practice and further supported by gains in life sciences. When it comes to energy companies, utilities, investors, and others in that ecosystem who are steering through a fast-shifting energy landscape, CRA's energy practice is still the advisor they rely on. During the quarter, the practice assisted a major California electric utility with its Integrated Resource Plan, helping to balance reliability, decarbonization, and affordability goals. The team also contributed to several efforts analyzing market design as questions mount about how electricity markets compensate generators and ensure resource adequacy. Additionally, the energy practice experienced strong activity from private capital clients seeking commercial and regulatory due diligence for investments in energy infrastructure, utilities, and increasingly digital infrastructure like data centers and network assets, where energy has become a key element of cost and investment strategy; these projects keep leveraging CRA's deep industry knowledge and analytical expertise to help clients assess opportunities throughout the evolving power and infrastructure sectors. Our life sciences team continues to take on early-stage assets while keeping a worldwide perspective. Take this quarter: we helped a client figure out how to handle a portfolio of neurological assets they'd just bought. On the U.S. side, our people evaluated what pricing and access could look like for that portfolio. Beyond that, we support major European markets, handling conditions ranging from bipolar disorder to Alzheimer's disease, and we offered data-backed guidance on clinical trial design as well as the sequencing of launches. When it comes to squeezing maximum value from our expert witness work, we keep pulling from lessons learned in strategy consulting for a pair of disputes involving new product launches. On the whole, I want to thank each of my colleagues for their efforts throughout the third quarter. CRA's solid results over the long run say a lot about the company's quality overall, since we keep assisting clients as they take on their most significant and intricate problems, and it shows we can seize growth opportunities available in the market. Now let's look at guidance for the first three quarters of fiscal 2025, measured on a constant currency basis against fiscal 2024: CRA brought in total revenue of $552.1 million along with non-GAAP EBITDA of $71.8 million, which works out to a margin of 13.0%. Because our business remains so robust and high in quality, we're increasing our revenue forecast and pushing up the lower end of our profit projection for the entire fiscal 2025 year, measured on a constant currency basis. Compared with fiscal 2024, our expectation now is that revenue will land somewhere from $740 million to $748 million, alongside a non-GAAP EBITDA margin somewhere between 12.6% and 13.0%. This revised guidance compares with a prior revenue span of $730 million to $745 million and an earlier EBITDA margin span of 12.3% to 13.0%. Keep this in mind: January 3, 2026 marks the close of our fiscal year, so there will be a 14th week included in the fourth quarter of 2025. Although we're happy with how CRA has performed so far in fiscal 2025, we stay aware that unsettled macroeconomic, business, and political conditions around the world could impact our business and our clients. Having said that, I'll hand the call to Chad, and after that to Eric, for some further remarks. Thanks, Paul, Chad.

Chad Holmes executive
#3

Hi, everybody. I'd like to bring you up to speed on our capital position and how we deployed capital in the quarter. We ended the quarter with $22.5 million in cash along with $95.0 million drawn on our revolving credit facility, which puts net debt at $72.5 million. Those numbers include $25 million in net payments we made over the quarter to pay down what we owed on the revolver. In the third quarter of 2025, we also spent $28.1 million in net cash to bring in and keep senior talent, plus $700,000 on capital expenditures. Returning capital to shareholders during the third quarter totaled $7.2 million, made up of $3.2 million in dividends and $4.0 million used to buy back roughly 22,000 shares at an average price of $185.74 per share. Right now, $10.9 million remains available under our share repurchase program. This morning, we announced that our quarterly cash dividend is rising 16%, from $0.49 to $0.57 per common share, which shows how confident we are in the quality of the business and reflects our dedication to giving capital back to shareholders; the growth and performance of CRA's business supports this new dividend amount, and it is more than four times larger than our first dividend in 2016. We closed the third quarter of fiscal 2025 with total liquidity of $123.6 million, which is $22.5 million in cash and cash equivalents plus another $101.1 million of available capacity on our line of credit; with that, I'll hand the call to Eric for a few closing remarks.

Eric Nierenberg executive
#4

Eric, thank you, Chad. Just a note that a more detailed discussion of our financial results can be found in the Prepared CFO Remarks within the Investor Relations area of our site. Ahead of taking questions, I'd like to share several extra figures regarding how we performed during the third quarter of fiscal 2025. Regarding our consultant headcount, we finished the quarter with 968 people, made up of 164 officers, 567 other senior staff, and 237 junior staff. That marks a 1.0% decline versus a year earlier, when the figure was 978 consultants at the close of Q3 fiscal 2024, and a 3.3% rise sequentially from the 937 consultants reported at the close of Q2 fiscal 2025. Non-GAAP selling, general, and administrative expenses — after excluding the 1.8% tied to commissions paid to non-employee experts — came to 16.3% of revenue in the third quarter of fiscal 2025, versus 16.2% during the same period last year. On a non-GAAP basis, our effective tax rate for the third quarter of fiscal 2025 was 28.8%, compared with 28.5% on a non-GAAP basis in the third quarter of fiscal 2024. Moving to the balance sheet, DSO was 115 days at the close of the third quarter, up from the 110 days at the close of the second quarter of fiscal 2025. The third quarter DSO broke down as 70 days billed and 45 days unbilled; that wraps up our prepared remarks; we'll now take questions. Rob, go ahead.

Andrew Nicholas analyst
#5

Hello, and good morning. I appreciate you taking my questions. Let's begin with the topic of headcount. In fact, I believe I posed something quite similar around this point last year, but I was somewhat taken aback that we didn't witness a more pronounced increase in junior consultants from one quarter to the next, considering the usual seasonal patterns at play. Compared with prior periods, the proportion of junior staff to senior staff also appears fairly modest. Andrew, I just want to know if that share can hold up, if there's anything going on beneath the surface that explains why the mix has moved this way, and maybe your bigger-picture view on how headcount will grow in health care or healthcare over the next few quarters.

Paul Maleh executive
#6

Sure. Morning, Andrew. The best place to begin is this: over CRA's entire history, we've kept sowing seeds of growth, so to speak. As consultants and as the firm's management, our task is to raise the odds those seeds pay off and to put the right money in at the right moments. The headcount volatility or changes that you've seen, say in the last 12 to 24 months, are really us evaluating these growth opportunities at times where we think the potential is not there for future growth; we redeploy the assets to somewhere else in the firm. The parts of the company that are growing are receiving headcount growth. When we identify opportunities that don't seem promising, those resources get shifted to other areas. That's the first piece of my response. None of the practices that are growing are being neglected. Actually, they're expanding and doing so profitably. Another thing I'd like to point out is that, as I recall, we've brought on close to 20 new Vice Presidents through lateral hires so far in 2025. As a result, the Vice President headcount will end up disproportionately large compared with staffing levels in other areas of the company. Once these people begin to get up to speed and income begins to show up, I think you can reasonably expect that we'll add layers beneath those professionals; usually we don't do both at once, since we think the near-term need can be handled by the capacity we already have. My sense is that over the medium to longer horizon, you ought to see staffing increases coming in at about the same pace as top-line growth. It's really only when hiring happens quickly, or when assets are being shifted around, that certain metrics like the ones we've shared in recent quarters might appear.

Andrew Nicholas analyst
#7

That all makes a lot of sense. Thanks for the detail, I suppose. Kind of on the same topic, and maybe what you just said helps me with this next one too. Regarding overall bill rates, revenue growth was once again very strong this quarter, utilization was very strong as well but pretty much in line with what you had this time a year ago; it looks to me like aggregate bill rates are up perhaps low double digits, if I'm calculating right. I'm just curious whether you could break that down, verify it, and then sort of explain what's behind it. Is it simply rate card increases, is it mix, or some other factors I'm not considering?

Paul Maleh executive
#8

Sure. Let me begin by sort of giving myself a pat on the back, giving the company a pat on the back here, which is that we've delivered this consistent exceptional performance, and at times we take for granted the statistics we report each quarter. Utilization might be in line with a year ago, but remember it's 77% and a year ago it was 76%. We're always measuring ourselves against peak levels of performance, and that applies to utilization, it applies to revenue, and it applies to profitability throughout the firm. I just don't want that to be missed as a company here for what we're delivering when it comes to the rates. Our rate increases are typically set near the end of the prior year and carry into the start of the current year. Rate increases occurred, most of it during Q1 of fiscal 2025. As new projects come online, we get to realize more of the full benefit of that rate increase. I believe in 2025, I think the effective rate increase is roughly 3%, more or less. That has held. We don't see any change in write offs, we don't see any change of reserves. In fact, we're quite pleased with the repeat client activity we're having during the year. The reason I bring that up is that's a sign that the value perceived is still quite high by our clients.

Andrew Nicholas analyst
#9

Okay. Can we reasonably expect the same kind of upticks moving ahead? Is that a sensible way for us to frame how we think about billing rates over the medium term?

Paul Maleh executive
#10

Whenever you begin with a premise that bill rates sit somewhere between 2% and 4%, and then you recognize that this doesn't occur all at once on January 1, but typically takes place as new project inflow arrives at the firm, I'd say that assumption holds up. My consulting colleagues, I'm sure, would likely argue the point, but in my view those rate hikes could go even higher. Ensuring the value we deliver to our clients always comes first is what we care about most.

Andrew Nicholas analyst
#11

That makes sense. One final item from me, and it concerns growth outside the U.S. I believe you brought up certain practices performing very strongly abroad. During the quarter, a handful of engagements or projects you had underway produced that kind of 30%+ expansion. Are there any broader secular trends overseas that you might also highlight as fueling faster growth there compared with the U.S., and perhaps some thoughts on how lasting those trends could prove moving forward? Thanks once more.

Paul Maleh executive
#12

Certainly. Thank you, Andrew. Once again I want to begin by praising what our competition practice in Europe has delivered. For a practice — a sub practice — that has existed for as long as theirs has, to achieve 30% growth year over year on straight time and material type revenue, they are by far the highest quality provider of services in the antitrust and competition economics space, and that is truly remarkable. As for the secular shifts, Europe has seen less volatility when it comes to enforcement stance. Before 2025 they were very pro enforcement, and that has carried on in the U.S. Perhaps there have been a few starts and stops tied to the transition toward the new administration and its new position on mergers and regulatory oversight. I would say what matters more is the steadiness of strong enforcement, you know, when you set that against North America. It all begins with just the outstanding quality of the team we have over there in Europe.

Andrew Nicholas analyst
#13

Andrew Nicholas here, thanks once more.

Marc Riddick analyst
#14

hello there, and good morning to you.

Paul Maleh executive
#15

morning to you as well, Marc.

Marc Riddick analyst
#16

First off, I appreciate the thoroughness and nuance you gave us in the prepared remarks. I'd like to spend a moment on the legal and regulatory work you called out. It looks like that keeps ramping up. Could you maybe walk through some of the forces behind that? Perhaps more lately — it sounds fairly wide-ranging, but maybe a bit more texture on that side of client activity.

Paul Maleh executive
#17

Yeah, when I looked at the legal figures, I actually had team members verify those stats a second time. The level of expansion in new case filings and court decisions genuinely caught me off guard. I believe that's a positive signal for the quarters to come, as those matters look for consulting support. As for what we're observing, the practices that have always been sturdy keep bringing in really solid inflow activity: the antitrust and competition economics practice, the intellectual property practice, the forensic services practice, and we're noticing some early hints that momentum may be building in our finance practice. I think you'd describe it as wide-ranging. It's also a factor when I mention 7 of 11 practices expanding year over year and 4, or 5 — sorry, I'm losing count — 4 expanding double digit year over year. The inflow has been wide-ranging, and turning those opportunities into revenue and profits has been wide-ranging too. We're sitting in a fairly strong spot right now, and we're eager for the quarters ahead to find out whether those keep materializing.

Marc Riddick analyst
#18

I appreciate that extra detail, since those figures really stood out to me when you brought them up during your prepared remarks. It's helpful that you added more context. Naturally, we've observed the improvements from M&A activity and what that has represented, plus the momentum that, honestly, your team was outperforming the market with for some time in antitrust and competition economics. I was curious — it appears that we're, if we were considering typical visibility for this point in the year, since usually as we move toward Q4 and the holidays and so on, do you feel that this year offers a standard level of visibility regarding activity levels? It definitely looks like, based on the momentum you're seeing pretty much everywhere, that perhaps you have somewhat greater visibility than is usual at this point in the year.

Paul Maleh executive
#19

I believe I largely concur with what you've said. What provides me confidence and part of that visibility is truly the steadiness of results we've had throughout the year. I've also had comparable steadiness across fiscal 2024. Once we were three quarters into fiscal 2024, I cannot claim I felt any less confident than I feel right now, nor the reverse. Our initial three quarters back then were the strongest three quarters we recorded in 2024, and they are the strongest three quarters we've ever recorded when you consider 2025; we remain cautiously optimistic. I cannot say that visibility or the big long-term projects have grown in 2025 compared with 2024, but I'm pleased with our position.

Marc Riddick analyst
#20

All right. One final item from my side — do you have a feeling that certain customer verticals might be busier than others in some areas of the business, or did any of them particularly catch your attention during the past several months?

Paul Maleh executive
#21

Beyond the sector illustrations we've been providing in energy, where demand has kept coming in quite robust, we may be witnessing some steadiness in the climb within pharma and life sciences; as for litigation work, that's genuinely not tied to any specific industry. We're pleased that merger dollar values have risen. On the other hand, the count of deals announced so far hasn't grown, or is marginally lower. A few things balance each other out. Big, intricate engagements usually call for consulting support; we'll find out what the coming quarters bring.

Marc Riddick analyst
#22

Excellent. Thank you very much.

Paul Maleh executive
#23

Thank you, Marc.

Kevin Steinke analyst
#24

Hi there, morning. Paul, Chad, and Eric.

Paul Maleh executive
#25

Morning, Kevin. Morning.

Kevin Steinke analyst
#26

To kick things off, I'd like to ask how much overall scrutiny there is right now from regulators when it comes to antitrust and M&A. You've mentioned that intense examination continues abroad, yet judging by the numbers you're reporting, it doesn't look like we've actually witnessed much of a real shift in the regulatory landscape. In the U.S., would you agree that's a fair way to describe things?

Paul Maleh executive
#27

All I can really speak to is what we're seeing directly when it comes to projects flowing in. That's a tough question to answer. I've noticed a drop-off in antitrust enforcement even as our antitrust and competition economics practice keeps posting one record quarter after another. Some shifts are obviously underway. Exactly how they play out, or how soon that happens, is still unclear. So far, as far as the work arriving at CRA goes, I haven't observed any shrinking tied to the new posture.

Kevin Steinke analyst
#28

All right, thank you. You actually brought that up just a moment ago. My question was going to be about life sciences. It seems as though the pipeline might be picking up somewhat there. Could you perhaps describe a few of the things you're seeing happen in that area, and also the outlook as we go forward over the coming several quarters?

Paul Maleh executive
#29

For quite a few quarters at this point, we've described how life sciences has performed in a somewhat sawtooth manner, yet in 2025 a mild upward tilt is beginning to appear — possibly a sawtooth shape; within that practice, we're still expanding at roughly mid single digits so far this year. Those early signs please me, though I won't yet claim victory or a disproportionate rise ahead across the coming quarters. Obviously, plenty of market forces exist that would back continued expansion. Nobody, I believe, could argue the pharma sector is growing less complicated. Drug pricing involves far more complexity, the rollout involves far more complexity, unfavored nation status and similar matters too. In my view, the wider market dynamics favor our services. Certain cost disciplines, I believe, have stood in the way of stronger growth from one quarter to the next.

Kevin Steinke analyst
#30

All right, that does help. And then I'd like to inquire about the intellectual property practice as well. As I recall, during each of the past 2 quarters, you mentioned that this one is expanding at a rate in the double digits. In the remarks you prepared, you brought up the example connected to COVID. I believe I've additionally heard you mention previously that perhaps AI will generate a great number of problems within the intellectual property area. So I'm simply curious about what the future holds for this practice and whether demand for it can be sustained moving forward.

Paul Maleh executive
#31

Certainly. What the intellectual property practice is accomplishing at present strikes me as truly remarkable. You brought up how the market is behaving. At this moment, they are discovering chances to team up between intellectual property and our antitrust and competition economics practice, plus chances to team up with the finance practice. Those forces driving demand, in my view, are not disappearing. My reason for calling attention to these collaborations across practices is that usually, collaborations spanning different practices signal matters of greater complexity and greater size. The teaming that's taking place makes me genuinely pleased, and I'm also quite glad to observe that our IP practice appears to be a go-to provider across a large number of these engagements.

Analyst analyst
#32

Great. Finally, I was hoping to inquire about how robust VP hiring has been — you know, on the Vice President front — for, you know, 2025 so far. It appeared that during the past 3 months you issued a fair number of press releases regarding newly appointed VPs throughout your different practices. Could you just address the recruiting pipeline? I mean, is anything happening in the market that lets you bring in talent faster, or simply kind of address that surge of talent you've observed here across the last several months?

Paul Maleh executive
#33

I've felt quite delighted by the wave of new Vice President colleagues arriving at CRA during 2025. Chad and his team have performed remarkably well in spotting colleagues as they engage with the practices. Another thing worth mentioning, I think, is that those we are bringing aboard enjoy abundant options. Right; they could essentially join any other consulting firm in our marketplace. That they perceive the value proposition at CRA is what has thrilled me the most. They perceive the success we are achieving in the marketplace. They perceive the success that people who come to CRA are achieving when it comes to how their business ramps up. It is a wonderful collaborative effort involving finding the individuals, conveying the value proposition to those individuals, and equally important is showing how successful those individuals become once they arrive at CRA. The pipeline is rich, but we're being very selective about whom we bring in. So far, we're pretty excited about the 20 or so colleagues that have joined.

Kevin Steinke analyst
#34

All right, that’s encouraging, and thanks for letting me ask. I’ll hand it back over.

Paul Maleh executive
#35

Wonderful. Thanks, Kevin.

Paul Maleh executive
#36

Once more, we're grateful to all of you for being with us. Your time and your interest in CRA mean a lot to us. Over the months ahead, we'll be taking part in investor meetings, and we're eager to share news about how we're doing on our fourth quarter call early next year. That said, we're now wrapping up today's call. Thanks to each of you.

Operator operator
#37

That wraps up the call for today. At this point you're free to hang up your lines. We appreciate everyone for joining.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete CRA International, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to CRA International, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.